PDF(Pubmed)
Abstract：
A central component in the introduction of a novel surgical procedure or technique is an evaluation of its cost efficiency when compared with a benchmark standard of care. Accurate assessment of costs is thus essential in ensuring appropriate allocation of resources within a healthcare system. The treatment of kidney failure requires a significant volume of resources, and vascular access provision is the main modifiable cost. The costs of providing this service are obscured by generic NHS reference costs, which lack adequate granularity to allow meaningful comparisons between treatments. The aim of this systematic review will be to assess the reporting of procedural costs in all published economic analyses of vascular access surgery and perform a comparison of the reported procedural costs involved in arteriovenous fistula (AVF) and arteriovenous graft (AVG) creation. This will provide an estimate as to the accuracy of the NHS reference costs in this field.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be followed. A systematic search will be performed of the MEDLINE, Embase and Cochrane databases to identify full-text economic analyses of vascular access for haemodialysis in which the procedural cost of AVF or AVG creation is reported. Publications in English from 1 January 2000 to 30 August 2023, will be eligible for inclusion. Studies will be selected by title and abstract review, followed by a full-text review using inclusion and exclusion criteria. Studies not reporting the procedural costs of surgery will be excluded. Data collected will pertain to procedural costs of AVF and AVG creation. Costs will be adjusted to a common currency using a gross domestic product (GDP) deflator index and conversion rates based on purchasing power parities for GDP. Comparison with NHS reference costs will indicate their reliability for use in future economic analyses in this field.
Ethical approval is not required for this systematic review. Findings will be disseminated through peer-reviewed publications and conference presentations.
CRD42023458779.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be followed. A systematic search will be performed of the MEDLINE, Embase and Cochrane databases to identify full-text economic analyses of vascular access for haemodialysis in which the procedural cost of AVF or AVG creation is reported. Publications in English from 1 January 2000 to 30 August 2023, will be eligible for inclusion. Studies will be selected by title and abstract review, followed by a full-text review using inclusion and exclusion criteria. Studies not reporting the procedural costs of surgery will be excluded. Data collected will pertain to procedural costs of AVF and AVG creation. Costs will be adjusted to a common currency using a gross domestic product (GDP) deflator index and conversion rates based on purchasing power parities for GDP. Comparison with NHS reference costs will indicate their reliability for use in future economic analyses in this field.
Ethical approval is not required for this systematic review. Findings will be disseminated through peer-reviewed publications and conference presentations.
CRD42023458779.
摘要：
背景：引入新型外科手术或技术的核心组成部分是与基准护理标准相比对其成本效率的评估。因此，准确评估成本对于确保医疗保健系统内资源的适当分配至关重要。肾衰竭的治疗需要大量的资源,血管通路供应是主要的可修改成本。提供这项服务的成本被一般的NHS参考成本所掩盖，缺乏足够的粒度来允许治疗之间有意义的比较。本系统评价的目的是评估所有已发表的血管通路手术经济分析中的程序成本报告，并比较动静脉瘘（AVF）和动静脉移植物（AVG）创建中报告的程序成本。这将提供对该领域NHS参考成本准确性的估计。
方法：将遵循系统评价和荟萃分析指南的首选报告项目。将对MEDLINE进行系统搜索，Embase和Cochrane数据库用于确定血液透析血管通路的全文经济分析，其中报告了AVF或AVG创建的程序成本。2000年1月1日至2023年8月30日的英文出版物将有资格列入。研究将通过标题和摘要评论来选择，然后使用纳入和排除标准进行全文审查.不报告手术费用的研究将被排除。收集的数据将涉及AVF和AVG创建的程序成本。将使用国内生产总值（GDP）平减指数和基于GDP购买力平价的换算率将成本调整为通用货币。与NHS参考成本的比较将表明它们在该领域未来的经济分析中使用的可靠性。
背景：本系统评价不需要伦理批准。调查结果将通过同行评审的出版物和会议介绍进行传播。
■CRD42023458779。
方法：将遵循系统评价和荟萃分析指南的首选报告项目。将对MEDLINE进行系统搜索，Embase和Cochrane数据库用于确定血液透析血管通路的全文经济分析，其中报告了AVF或AVG创建的程序成本。2000年1月1日至2023年8月30日的英文出版物将有资格列入。研究将通过标题和摘要评论来选择，然后使用纳入和排除标准进行全文审查.不报告手术费用的研究将被排除。收集的数据将涉及AVF和AVG创建的程序成本。将使用国内生产总值（GDP）平减指数和基于GDP购买力平价的换算率将成本调整为通用货币。与NHS参考成本的比较将表明它们在该领域未来的经济分析中使用的可靠性。
背景：本系统评价不需要伦理批准。调查结果将通过同行评审的出版物和会议介绍进行传播。
■CRD42023458779。
